Patent Application
20230263787
The inventors have considered neuronal and axonal biology in relation to homeostatic axonal response of mitochondria to demyelination. Based on the axonal response of mitochondria to demyelination (ARMD) there is provided compositions and methods for neuroprotective treatments in demyelinating conditions and methods of determining the same.
Studies performed in multiple sclerosis (MS) patients have shown that the demyelinated regions contain transected axons. In this most common inflammatory demyelinating disorder of the CNS, axon transection is most prominent in acutely demyelinated regions and evident to a lesser extent in those axons that survived the acute myelin attack and had become chronically demyelinated. Animal models of the early stage of MS (relapsing MS), experimental autoimmune encephalomyelitis, show inflammation mediated damage to myelin, mitochondria and axons, irrespective of the myelin status. Furthermore, adaptive immunity can directly transect axons, through cytotoxic T cells, presumably without involving mitochondria. These studies reflect the multiple mechanisms of axon injury in MS and highlight the major role played by inflammation at the early stage of the disease. Whilst the therapeutic goal is to to modulate inflammation, in particular the adaptive immune response, and prevent the formation of new demyelinating lesions in MS has largely been achieved, such disease modifying therapy (DMT) in relapsing MS neither prevents the transition to progressive MS (late stage) nor curtails the worsening of progressive MS. Despite the DMT, acute demyelination continues at the slowly expanding edges of established or chronic MS lesions, where acutely demyelinated axons are transected.
Demyelination contributes to the loss of axons and the progression of neurological disability in demyelinating disorders, including MS, where axons are transected during inflammatory-mediated early demyelination of white matter and later axons degenerate due to chronic demyelination.
The absence of effective treatments for progressive MS is an urgent unmet need. Whilst immune-modulatory treatments for the inflammatory demyelinating early phase of MS have had some success, the consequence of demyelination on neuronal and axonal biology remains poorly understood.
Notably, there are no neuroprotective strategies to preserve the acutely demyelinated axon, highlighting the urgent unmet clinical need. One underlying contributor to the axonal degeneration is an imbalance between the increased energy demands of nerve conduction and the generation of ATP in the demyelinated axon.
In demyelinating disorders, such as MS, HIV neuropathy and diabetic peripheral neuropathy, perturbation of mitochondrial respiratory chain in neurons constitutes an additional contributor to the energy failure state of demyelinated axons. For example, in progressive MS, perturbation of the mitochondrial respiratory chain, including complex IV deficiency, is a robust finding in cortical neurons. Mitochondrial respiratory chain complex IV or cytochrome c oxidase (COX), the terminal complex of the electron transport chain, can be deficient in multiple neuronal subtypes. Complex IV deficiency in neurons impairs anterograde mitochondrial transport, depletes axonal mitochondria and causes degeneration of myelinated axons [21]. As the loss of complex IV deficient neurons is a late phenomenon, demyelination of these neurons will further compromise the energy failure state.
As discussed, an underlying contributor to the axonal degeneration is an imbalance between the increased energy demands of nerve conduction and the generation of ATP in the demyelinated axon. To help compensate for this imbalance, axonal mitochondrial content is consistently increased following demyelination.
Myelination is known to conserve neuronal energy by clustering voltage-gated Na channels to the nodes of Ranvier, enabling saltatory conduction of action potentials. This energy efficiency decreases the reliance on mitochondria, resulting to changes in axonal mitochondrial distribution, content and activity. Thus, the influence of myelination on axonal energy demand is akin to a brake on mitochondrial dynamics and content in the axon. In contrast, the demyelinated axon is bioenergetically challenged, given the increased reliance on the Na+K+-ATPase to maintain the resting membrane potential and axonal integrity due to the redistribution of ion channels. Consequently, mitochondria gather again in abundance in the demyelinated axons, and interrupting this exacerbates axonal degeneration.
The present inventors have shown that the mitochondrial homeostatic response to demyelination alone is insufficient to protect the axon from degeneration. Suitably, targeting mitochondrial biogenesis and mitochondrial transport from the cell body to axon, protects acutely demyelinated axons from degeneration. Crucially, enhancing mitochondrial dynamics can protect the vulnerable, acute demyelinated axons, irrespective of the presence or absence of aberrations in mitochondrial bioenergetic function. Consequently, increased mobilisation of mitochondria from the neuronal cell body to the axon is a novel neuroprotective strategy for the vulnerable, acutely demyelinated axon. The inventors propose that promoting ARMD is a crucial preceding step for implementing potential regenerative strategies for demyelinating disorders. Accordingly, there is provided a neuroprotective strategy, targeting both the early and later phases of clinical demyelinating diseases, that addresses the key substrate of neurological disability - the vulnerable axon. In addition, the inventors have discovered the importance of axonal mitochondrial respiratory chain complex IV (COX) activity in demyelinated axons. Accordingly, the invention also includes the regulation and preservation of axonal mitochondrial respiratory chain complex IV in demyelinated axons.
According to a first aspect of the present invention there is provided a method of increasing mobilization of mitochondria from the neuronal cell body to the demyelinated axon to treat demyelinating disorders and provide a novel neuroprotective strategy for vulnerable acutely demyelinated axons. It is considered promoting ARMD will, alone or in combination, provide regenerative strategies in demyelinating disorders.
Suitably the mobilisation may be provided by increasing the synthesis or production of new mitochondria (mitochondrial biogenesis) in neurons and / or over expression of proteins that are involved with the forward movement or anterograde transport of mitochondria such as kinesin family of proteins. Suitably this provides a method to protect demyelinated axons and thus be suitable to treat demyelinating disorders. Suitably the mobilisation may be provided by over expression of peroxisome proliferator-activated receptor gamma (PPAR-y) coactivator 1-alpha (PGC1a) or a down stream factor thereof, which increases the mobilisation of mitochondria in neurons. Suitably a down stream factor may be selected from a list comprising transcription factor A mitochondria (TFAM) and PPARS to increase the mobilisation of mitochondria in neurons. Suitably mobilisation may be induced by PGC1a overexpression or provision of a thiazolidinedione which increase the mobilisation of mitochondria in neurons, for example pioglitazone or rosiglitazone to a subject.
Suitably a neuroprotective strategy is provided to demyelinating diseases which is distinguished from classical treatments of neurodegenerative disorders and primary mitochondrial diseases.
Suitably the neuroprotective strategy is particularly advantageous to treat demyelinating disorders. Suitably, the demyelinating disorder may be any disorder in which axonal demyelination occurs. Suitably, the demyelinating disorder may be a disorder that causes demyelination of neurons in the central nervous system. Suitably, the demyelinating disorder may be a disorder that causes demyelination of neurons in the peripheral nervous system. Suitably, the demyelinating disorder may be a disorder that causes demyelination of neurons in both the central nervous system and peripheral nervous system. Suitably, the demyelinating disorder may be any disorder such as MS, HIV and diabetic neuropathy, chronic inflammatory demyelinating polyradiculoneuropathy (ClDP), autoimmune encephalitis, acute disseminated encephalomyelitis, transverse myelitis, Guillan-Barre Syndrome, Neuromyelitis Optica, Charcot-Marie-Tooth Disease, HTLV-l Associated Myelopathy, Balo’s disease or Schilder’s disease.
Suitably the neuroprotective strategy is particularly advantageous to treat experimentally induced demyelination or an animal model which is genetically predisposed to axonal demyelination. Suitably, the demyelination may be caused by experimental autoimmune encephalitis. Suitably, the demyelination may be caused by a T-cell receptor experimental autoimmune encephalitis transgenic mouse model. Suitably, the demyelination may be caused by Theiler’s murine encephalomyelitis virus. Suitably, the demyelination may be induced by lysolecithin. Suitably, the demyelination may be induced by lipopolysaccharide. Suitably, the demyelination may be induced by cuprizone.
Targeting mitochondrial biogenesis and mitochondrial dynamics to boost the energy producing capacity of neurons is advantageously realised by the inventors to counter demyelination which rapidly leads to an energy deficient state in axons and leads to long term damage in demyelinating disorders.
Suitably mobilisation may be provided by pharmacological application of thiazolidinediones which increase the mobilisation of mitochondria in neurons, for example pioglitazone or rosiglitazone and / or the use of small molecules and drugs that increase the anterograde transport of mitochondria in neurons can also be used, following a phenotypic screening assay of compounds and drugs.
It is considered that treatment as discussed herein would be provided as an early initiation step and until both the damage to myelin is halted and the repair of myelin or remyelination is completed. It is considered that long term treatment may be required as demyelination is ongoing in some conditions such as MS.
It is considered that the proposed neuroprotective strategy of enhancing ARMD to be effective, will advantageously be combined with effective immunomodulatory therapies and with those that restore the myelin sheath to axons (remyelination therapy) [18]. The mechanisms of axon degeneration, such as by cytotoxic T cells mediated axonal transection and by free radical mediated damage to mitochondria in both myelinated and demyelinated axons require the inflammatory response in MS to be effectively controlled [23, 30, 49, 65]. The energy imbalance in chronically demyelinated axons can be partially restored by remyelination, which decreases the axonal mitochondrial content to a level that approaches that found in myelinated axons [81]. Remyelination addresses the long term protection of axons that have survived the acute destruction of their myelin sheath (chronically demyelinated axons). In contrast, the present neuroprotection strategy allows more axons to be saved during acute demyelination so that remyelination may restore the metabolic neuronal-glial cross talk in the long term [1, 18, 20]. Thus, the present neuroprotective model serves to bridge the crucial gap between immune therapy and regenerative therapy.
Suitably, the proposed neuroprotective strategy of enhancing ARMD may be used to combat demyelination in central nervous system neurons. Suitably, the proposed neuroprotective strategy of enhancing ARMD may be used to combat demyelination in peripheral nervous system neurons. Suitably, the proposed neuroprotective strategy of enhancing ARMD may be used to combat demyelination in central and peripheral nervous system neurons.
According to a second aspect of the present invention there is provided a method of increasing mobilization of mitochondria from the neuronal cell body to the demyelinated axon to provide a novel neuroprotective strategy for vulnerable acutely demyelinated axons in combination with a method of remyelination of the axon.
Suitably any methods known in the art in relation to remyelination of the axon can be used in combination.
Suitably the present invention provides a modulator of the PGC1a/PPAR-y pathway for use in combination with a remyelination causing agent. Suitably a modulator of the PGC1a/PPAR-y pathway may be selected from thiazolidinediones which increase the mobilisation of mitochondria in neurons, for example Pioglitazone and Rosiglitazone and / or the use of small molecules and drugs that increase the anterograde transport of mitochondria in neurons. Suitably remyelination agents may be selected from Metformin, Clemestine and Lipoic acid. Suitably any agent that enhances ARMD or mitochondrial mobility can be used in combination with remyelainting agents as known in the art.
Suitably, methods of controlling inflammatory response in MS or other demyelinating diseases can be utilised in combination with enhanced ARMD as discussed herein. This may also provide a separate aspect of the invention.
Suitably methods of increasing the supply of metabolic substrate to the axon, that is necessary for mitochondrial respiratory chain function in acutely and/or chronically demyelinated axons can be utilised in combination with enhanced ARMD as discussed herein. This may also provide a separate aspect of the invention.
According to a third aspect of the invention there is provided Pioglitazone or Rosiglitazone for use in the treatment of MS, HIV neuropathy or diabetic neuropathy. In particular for use in the treatment of MS, HIV neuropathy or diabetic neuropathy in those subjects in which nerve protection is required or advantageous.
According to a fourth aspect of the present invention there is provided Pioglitazone or Rosiglitazone in combination with a remyelination agent for use in the treatment of MS, HIV neuropathy or diabetic neuropathy. In particular for use in the treatment of MS, HIV neuropathy or diabetic neuropathy in those subjects in which nerve protection is required or advantageous. Suitably, remyelination agents may be selected from Metformin, Clemestine and Lipoic acid.
Suitably in the aspects of the invention there is provided the provision of metabolic substrate and / or anti-inflammatory agent to the demyelinated axons to enhance the ARMD strategy. Metabolic substrate and / or anti-inflammatory agent may be provided with remyelination therapy.
According to a fifth aspect of the present invention, there is provided an assay method to determine modulators of the PGC1a/PPAR-y pathway comprising the steps
Suitably other phenotypic screening assays which show increased mobilization of mitochondria from the neuronal cell body to the demyelinated axon could be utilised.
According to a sixth aspect of the present invention, there is provided a method of preserving or increasing the activity of axonal mitochondrial respiratory chain complex IV. Complex IV is essential for the optimal functioning of the electron transport chain and, thus, mitochondrial respiration. Complex IV is deficient within a subset of neurons in a number of demyelinating disorders such as MS, HIV and diabetes, due to decreased expression of complex IV proteins (because of mitochondrial DNA mutations). Increasing mitochondrial biogenesis in complex IV deficient neurons in complex IV knockout mice (inducible knockout), where complex IV expression is decreased, indicated a neuroprotective affect upon demyelination. In addition to this complex IV deficiency due to decreased expression of complex IV proteins, inflammatory response to demyelination frequently generate reactive oxygen species which damage mitochondria and remaining complex IV proteins via post-translational modifications. This is also evident in human diseases such as MS, and is the key driver of complex IV deficiency in experimental animal models with inflammatory demyelination. The inventors have determined that an increase in ARMD in demyelinated axons was not always accompanied with an increase in axonal mitochondrial respiratory chain complex IV (COX) activity. Furthermore, the inventors have discovered an inverse correlation between complex IV activity in demyelinated axons and axonal transection in experimental disease models. The results indicate inflammation induced post-translational modification of axonal mitochondrial proteins plays a crucial role in axonal degeneration witnessed in inflammatory conditions.
Suitably, the method may be used in the treatment of demyelinating disorders and to provide a novel neuroprotective strategy for vulnerable acutely demyelinated axons. Suitably, the method may be used in conjunction with any method to promote ARMD. Suitably, the method could be used in combination with the first to fourth aspects of the invention.
Suitably, the method could be used to preserve or enhance the activity of mitochondria which have been transported to the axon as a result of the increase in ARMD. Suitably, the method could be used to treat axonal demyelination in neurons which show a deficit in COX activity. Suitably, the method could be used to treat axonal demyelination in neurons which show a deficit in COX expression. Suitably, the method of preserving or increasing COX activity could be used in the treatment of conditions where complex IV activity is deficient, such as MS, HIV, Diabetes and rare cases of primary or inherited mitochondrial disease. Suitably, the method of preserving or increasing COX activity may be achieved by limiting damage to COX. Suitably, limiting damage to COX may be achieved through immunomodulatory therapy.
Suitably, the method of preserving or up-regulating COX activity may include the prevention of post-translational modification of COX proteins, by targeting the inflammatory response. Suitably, the method of preserving or up-regulating COX activity may include increasing mitochondrial biogenesis. Suitably, the method of up-regulating COX activity may include up-regulating the expression of the gene(s) responsible for encoding COX protein. Suitably the method may include treating a subject or neuron with Pioglitazone or Rosiglitazone.
Each document, reference, patent application or patent cited in this text is expressly incorporated herein in their entirety by reference, which means it should be read and considered by the reader as part of this text. That the document, reference, patent application or patent cited in the text is not repeated in this text is merely for reasons of conciseness.
Reference to cited material or information contained in the text should not be understood as a concession that the material or information was part of the common general knowledge or was known in any country.
As used herein, the articles “a” and “an” refer to one or to more than one (for example to at least one) of the grammatical object of the article.
“About” shall generally mean an acceptable degree of error for the quantity measured given the nature or precision of the measurements.
Throughout the specification, unless the context demands otherwise, the terms ‘comprise’ or ‘include’, or variations such as ‘comprises’ or ‘comprising’, ‘includes’ or ‘including’ will be understood to imply the includes of a stated integer or group of integers, but not the exclusion of any other integer or group of integers.
Embodiments of the present invention will now be described, by way of example only, with reference to the accompanying drawings in which:
a: Mitochondria within Purkinje cells are labelled in live cerebellar slice cultures, using lentivirus-mitochondria-targeted mEOS2 (ai, green). Photoconversion of mitochondria within the proximal axon segment adjacent to the Purkinje cell body [green to red conversion in the region of interest (ROI) shown in aii-aiv], enables the tracking of mitochondria from the cell body to the axon (anterograde, left to right).
b-c: Following photoconversion, time lapse imaging of the ROI over 20 minutes shows newly transported mitochondria (green) amongst the photoconverted mitochondria (red) in a myelinated axon (b) and a demyelinated axon (c). SCoRe was used to determine the myelination status of the mEOS2 labeled axons (
The majority of the photoconverted mitochondria remained stationary (b-c, red), while the newly transported mitochondria to the axon (b-c, green) continued to move (see videos for confirmation, online resource) and sometimes co-localised with the stationary mitochondria (presumably fused).
d-e: Kymographs of the green fluorescence channel show an abundance of mitochondria moving from the cell body to the ROI (left to right, anterograde transport) in demyelinated axons (e) compared with myelinated axons (d). See videos 1-5, online resource, for myelinated axons and videos 6-10, online resource, for demyelinated axons.
f-h: Quantitation of newly transported mitochondria (green) from the cell body to the ROI shows a significant increase in the number (f), area (g) and speed (h) of motile mitochondria in the demyelinated axons compared with myelinated axons. The number of retrograde moving mitochondria from the distal demyelinated axon segment to the ROI is also significantly increased upon demyelination (f). Data presented as dot-plot with mean (bar) ± standard deviation (whiskers). *p<0.05, **p<0.01, ***p<0.001, ****P<0.0001 using Mann-Whitney-U test.
i-j: Mitochondrial content of acutely demyelinated and non-transected axons gradually increases and peaks at 5 days in cerebellar slice cultures, following exposure to lysolecithin for 17 hours (i). The same peak is observed at 7 days, in vivo, following focal lysolecithin injection to the spinal cord (dorsal columns) of wild type mice (j). Each data point indicates the mean value of 20 axons from slice preparations or each animal. Statistical significance was determined using Kruskal-Wallis test.
k-l: Axonal injury following demyelination, judged by axon bulbs (transected axons), peaks 2-4 days earlier than the mitochondrial content in demyelinated axons in both cerebellar slices (k) and in vivo (I). Statistical significance was determined using Kruskal-Wallis test. ARMD: axonal mitochondrial response to demyelination.
a: Following photoconversion of the mEOS2 labeled mitochondria in the proximal axon segment (green to red), time lapse images indicate the anterograde movement of newly transported mitochondria from the unmyelinated DRG neuronal cell body to the proximal axon segment (left to right, see videos, online resource). Over-expression of Mitochondrial Rho GTPase 1 (Miro1) and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC1α) in DRG neurons in culture using lentiviruses as well as exposure of DRG neurons to 2 µM pioglitazone, a thiazolidinedione, enhances anterograde transport of mitochondria, as shown in kymographs and videos, online resource.
b-d: Quantitation of the newly transported mitochondria in the proximal axon segment of unmyelinated axons (green) indicates a significant increase in the number of mitochondria mobilising from the DRG neuronal cell body to the proximal axon segment following over-expression of Miro1 (b) and PGC1α (c) and exposure to pioglitazone (d) compared with untreated DRG neurons (ctl: control). The speed of anterograde moving mitochondria is significantly greater with the over-expression of PGC1α and exposure to pioglitazone. The size of the anterograde moving mitochondria remained unchanged.
Unlike Miro1, both PGC1α over-expression in DRG neurons and exposure to 2 µM pioglitazone significantly increase the size of the stationary mitochondria (red), and the total axonal mitochondrial content.
e-g: PGC1α and Miro1 over-expression as well as the application of pioglitazone to DRG neurons did not significantly alter the anterograde and retrograde transport of lysosomes within unmyelinated axons.
h-j: Similar to unmyelinated axons, Miro1 over-expression does not significantly alter the mitochondrial content within myelinated axons, whilst both PGC1α over-expression and application of pioglitazone significantly increase the axonal mitochondrial content within myelinated axons, in vitro.
Data presented as dot-plot with mean (bar) ± standard deviation (whiskers). *p<0.05, **p<0.01 and ***p<0.001 using Mann-Whitney-U test once Kruskal-Wallis test showed a p<0.05 in multiple subgroup comparisons.
a-b: The inventors labelled dorsal root ganglia (DRG) neurons by applying lentivirus-mKate2 (red) to the cell body chamber while MBP produced by oligodendrocytes in the other chamber were labeled using lentivirus M1-M4 (green) (a-b). Prior to demyelination (pre-DM), live images identify myelinated axonal segments in the co-culture chamber (ai and bi, arrows). Following demyelination (post-DM), by exposing to lysolecithin for 2 hours, live imaging shows damaged MBP-positive structures (aii and bii, arrows). The inventors then targeted mitochondria in neurons by applying lentivirus-Miro1, lentivirus-PGC1α and pioglitazone to the neuronal cell body chamber (treated, shown in bi and bii), prior to demyelination. All three manipulations protected the acutely demyelinated axonal segments (b, red) compared with untreated co-culture chambers (a, red).
c: For quantitation, axons were identified as intact (green outlined bar charts), beaded (orange outlined bar charts) and fragmented (red outlined bar charts) based on mKate2 signal, both prior to and following demyelination. Quantitation of axon injury following demyelination revealed a significant decrease in the proportion of demyelinated axons that are fragmented and a significant increase in demyelinated axons that remain intact, when the neuronal cell bodies were exposed to lentivirus-Miro1, lentiviris-PGC1α and pioglitazone (c). PGC1α inhibitor significantly diminished the protective effect of pioglitazone on demyelinated axons. Controls shown were exposed to lentivirus-mKate2. *p<0.05 and **p<0.01 using Mann-Whitney-U test, once Kruskal-Wallis test showed a p<0.05 in multiple subgroup comparisons.
d-i: The inventors detected axon bulbs (d, insert) when cerebellar slice cultures were demyelinated using lysolecithin (0.5 mg/ml) for 17 hours (d). Application of 40 µM pioglitazone to cerebellar slice cultures prior to lysolecithin-induced demyelination significantly decreased the extent of axon bulb formation compared with solvent (DMSO) only controls (f). Axonal mitochondrial content increased upon demyelination of cerebellar slices (g and h), consistent with homeostatic ARMD. The application of pioglitazone significantly increased the mitochondrial content of myelinated axons (i, pioglit+lyso-), compared with untreated cerebellar slices (i, pioglit-lyso-),). ***p<0.001 using Mann-Whitney-U test.
j-m: Demyelination of the spinal cord of wild type mice in vivo, using focal injection of lysolecithin (DM pioglit-) to the dorsal column, increases axon bulb formation (j) compared with non-demyelinated wild type mice (not shown) at 3 days post lesioning. Pioglitazone in diet for 6 weeks (120 mg/Kg diet), prior to focal spinal cord demyelination, significantly decreased axon bulb formation in wild type mice (k, DM pioglit+ and I) compared with controls on chow diet (j, DM pioglit- and I). The inventors did not detect a significant change in DAPI+ cells and Iba1 + cells in lesions with pioglitazone treatment. Mitochondrial content of both myelinated (m, DM-) and demyelinated axons (m, DM+) significantly increased following dietary pioglitazone in wild type mice (m, pioglit+) compared with control (m, pioglit-). Data presented as dot-plot with mean (bar) ± standard deviation (whiskers). *p<0.05 and **p<0.01 using Mann-Whitney-U test. DM: demyelinated. MBP: myelin basic protein. NF: neurofilament. Pioglit: pioglitazone.
a-b: In progressive MS, dorsal root ganglia (DRG) neurons that lack mitochondrial complex IV and contain complex ll (stained blue by COX/SDH histochemistry, insert in b), termed respiratory deficient, are abundant (b) compared with controls (a). The majority of neurons show intact complex IV in controls (stained brown, insert in a).
c: Quantitation of DRG in progressive MS identified significantly more respiratory deficient neurons in lumbar DRGs compared with controls (p<0.0001). Respiratory deficient neurons tended to be more prevalent in lumbar DRG than cervical DRG [the broken lines (c) indicate data from the same case]. In Parkinson’s disease the mean respiratory deficient neurons in lumbar DRG is 28.77% (SD = 13.66, n=3) and the mean is 33.51% (SD = 13.66, n=2) in motor neuron disease (MND) lumbar DRG (not shown). Data presented as dot-plot with mean (bar) ± standard deviation (whiskers). ****P<0.0001 using Mann-Whitney-U test and Kruskal-Wallis test showed a p<0.0001 in multiple subgroup comparisons.
d: Chronic spinal cord lesions in dorsal columns, at the corresponding dorsal root entry zone, of six progressive MS cases enabled the impact of respiratory deficient neurons on the mitochondrial parameters of demyelinated axons to be assessed.
e: Mitochondrial content in demyelinated dorsal column axons at the root entry zone, as a percentage of axon area, correlated significantly (p=0.004, r2=0.904) and positively with the percentage of respiratory deficient proprioceptive neurons in lumbar DRG in progressive MS (ei).
Average size of mitochondria within demyelinated dorsal column axons correlated significantly (p=0.044, r2=0.677) and positively with the percentage of respiratory deficient proprioceptive neurons in lumbar DRG in progressive MS (eii).
Average number of mitochondria within demyelinated dorsal column axons at the root entry zone correlated significantly (p=0.026, r2=0.747) and positively with the percentage of respiratory deficient proprioceptive neurons in lumbar DRG in progressive MS (eiii).
As expected, the percentage of the axon occupied by mitochondria that lacked complex IV subunit-l correlated significantly (p=0.023, r2=0.763) with the percentage of respiratory deficient proprioceptive neurons in lumbar DRG in progressive MS (eiv).
a-c: DRG neuron-specific inducible knockout mice that lack protoheme IX farnesyltransferase [subunit 10 of complex IV (COX10), termed COX10Adv mutants) contain complex IV deficient DRG neurons (b), which are stained blue by the sequential COX/SDH histochemistry assay. DRG neurons with intact complex IV are stained brown in both wild type mice and COX10Adv mutants (a and b). The quantitation identified approximately 59% of the DRG neurons as respiratory deficient in COX10Adv mice (c, n=3) compared with none in controls (c, n=3).
d-f: Sequential COX histochemistry and immunofluorescent labeling method, as previously described, identifies both proprioceptive (NF200+peripherin-, in green) and nociceptive neurons (NF200-peripherin+, in red) in DRG that are respiratory deficient (lack of or decrease in intensity of brown staining following COX histochemistry, shown in grey scale images in di and ei) in COX10Adv mutants (ei), unlike wild type mice (di). The quantitation of complex IV within immunofluorescently labeled proprioceptive and nociceptive neurons, using densitometry, identifies approximately 59.33 +/- 8.14 % and 83.33 +/- 3.05% of proprioceptive and nociceptive neurons, respectively, in COX10Adv mutants to be lacking complex IV (f). Complex IV deficient neurons, judged by densitometric analysis of COX histochemistry, are not present within DRG from wild type mice (a).
g: Quantitation of proprioceptive (NF200-positive in green) and nociceptive (peripherin-positive in red) DRG neurons from 13 week old wild type (n=3) and COX10Adv mutants (n=3) shows similar proportion of proprioceptive and nociceptive neurons in both groups.
h-k: In focal lysolecithin-induced lesions of the dorsal columns, demyelinated axons (NF in blue) contain more mitochondria (j and k) than myelinated axons (h and i), when mitochondria are identified with complex ll 70 KDa subunit (red) labeling, in both wild type (h and j) and COX10Adv mutants (i and k). As expected, complex IV subunit-l (green) is lacking within axonal mitochondria in COX10Adv mutants (i and k).
l-o: Quantitation of mitochondria within demyelinated dorsal column axons from wild type mice and COX10Adv mutants shows a significantly greater mitochondrial occupancy (l) and mitochondrial size (m) as well as extent of mitochondria lacking complex IV subunit-l (o) in experimentally demyelinated COX10Adv mutants compared wild type mice. These findings are concordant with the positive correlations that the inventors observed between the extent of respiratory deficient proprioceptive neurons and the mitochondrial parameters within demyelinated dorsal column axons at the root entry zone in progressive MS (shown in
Data presented as dot-plot with mean (bar) ± standard deviation (whiskers).
a-c: To model complex IV deficiency in vitro, the inventors pharmacologically inhibited it using sodium azide (SA, at 100 µM for 16 hours), which significantly decreases complex IV activity in wild type DRG neurons (b and c), as expected, compared with controls (a and c). The inhibition of complex IV by SA is similarly effective in DRG neurons, where Miro1 and PGC1α are over-expressed, using lentiviruses, and when exposed to pioglitazone (c). Controls shown were exposed to lentivirus-mEOS2. Solvent (DMSO) only controls for pioglitazone treatment did not show a significant effect compared with lentivirus-mEOS2 controls without DMSO (not shown). ***p<0.001 using Mann-Whitney-U test and Kruskal-Wallis test showed a p<0.05 in multiple subgroup comparisons.
d: Mitochondrial respiration significantly decreases when DRG neurons that are over-expressing Miro1 are exposed to SA (100 µM for 16 hours) (d). Although mitochondrial respiration tends to decrease when DRG neurons that are over-expressing PGC1α and treated with pioglitazone are exposed to SA, the decrease is not statistically significant (d), despite the significant inhibition of complex IV activity (c). **p<0.01 using Mann-Whitney-U test and Kruskal-Wallis test showed a p<0.05 in multiple subgroup comparisons.
e-f: As expected, the number of mitochondria mobilising from the DRG neuronal cell body to the axon significantly decreases following inhibition of complex IV by SA (100 µM for 16 hours) compared with DRG neurons not exposed to SA. In contrast, SA does not significantly decrease the anterograde movement of mitochondria from the cell body to the axon in DRG neurons where Miro1 and PGC1α are over-expressed, using lentiviruses, and when DRG neurons are treated with pioglitazone (e). Kymographs show the improvement in the number of mitochondria mobilising from the complex IV deficient neuronal cell body to the axon, which is mediated by Miro1 (fii), PGC1α (fiii) and pioglitazone (fiv). **p<0.01 and ***p<0.001 using Mann-Whitney-U test and Kruskal-Wallis test showed a p<0.05 in multiple subgroup comparisons.
g-i: When dorsal column axons are demyelinated (g, DM) by focal lysolecithin injections to the dorsal columns of COX10Adv mutant mice with complex IV deficient DRG neurons, there is an abundance of axon bulbs at 3 days post lesioning (g and i). Pioglitazone in diet for 6 weeks (120 mg/Kg diet), prior to focal dorsal column demyelination, significantly decreased the axon bulb formation within the demyelinated area in COX10Adv mutant mice (h, DM pioglit+) compared with untreated COX10Adv mutants (g, DM pioglit-) after focal demyelination of dorsal columns (i). *p<0.05 and **p<0.01 using Mann-Whitney-U test.
j: Ca2+ fluorescence responses of dorsal column nuclei (DCN) synaptoneurosomes evoked by AMPA (40 µM) in the presence of cyclothiazide (20 µM) were significantly attenuated in COX10Adv mutant mice compared to wild type and the impairment was exacerbated in mice with dorsal column demyelination 3 days previously. Dietary treatment with pioglitazone for 6 weeks beforehand fully rescued the functional deficits. Responses of non-pioglitazone controls (treated with DMSO vehicle) showed no significant difference from naive controls (**p<0.01, ***p<0.001; One-Way ANOVA with Tukey’s test, n=4-10).
COX10Adv: Inducible and DRG neuron-specific (Adv: advillin) knock out of complex IV subunit 10 (COX10) in mice, with complex IV deficient DRG neurons.
Data presented as dot-plot with mean (bar) ± standard deviation (whiskers). DM: demyelinated. Pioglit: pioglitazone. SA: sodium azide, complex IV inhibitor. *p<0.05, **p<0.01 and ***p<0.001.
a-g: Energy efficiency offered by myelination is reflected by a decrease in mitochondrial content in myelinated axons compared with unmyelinated axons, which is elegantly illustrated by the healthy optic nerve (a-b) [5]. Immediately following myelin loss, the inventors show that mitochondria increasingly mobilise from the neuronal cell body to the acutely demyelinated axons, leading to a gradual increase in the axonal mitochondrial content (c and f), which the inventors term axonal response of mitochondria to demyelination (ARMD). ARMD is a homeostatic phenomenon that attempts to increase the energy producing capacity of the acutely demyelinated axons (hom-ARMD). However, hom-ARMD is not sufficient to protect the acutely demyelinated axon, which undergoes transection within days of myelin loss and where myelin debris is still evident (c). During the time that is required by hom-ARMD to increase the mitochondrial content of the demyelinated axons (days), towards the level of the unmyelinated axons, the acutely demyelinated axons are particularly vulnerable and degenerate (c and f). Increased mobilisation of mitochondria from the neuronal cell body to the axons, which results in an enhanced ARMD (enh-ARMD) in both wild type neurons and those with complex IV deficiency, protects the vulnerable acutely demyelinated axons (d and g). This novel neuroprotective strategy is crucial to protect the acutely demyelinated axons so that, subsequently, neurorestorative therapy like remyelination can be implemented in demyelinating disorders.
ARMD: axonal response of mitochondria to demyelination. DM: demyelinated axon. Enh-ARMD: enhanced ARMD. Hom-ARMD: homeostatic ARMD. M: myelinated axon. UM: unmyelinated axon.
The inventors propose a mechanism (
Currently, there is no effective neuroprotective therapy for demyelinating disorders, including MS. Whilst an existing strategy has sought to curtail the increased energy demand of demyelinated axon through drugs that inhibit sodium channels, although effective in experimental models, this has failed in clinical trials and is poorly tolerated by MS patients [27, 76]. This is perhaps not surprising because they perturb adaptive neuronal firing properties that are required for healthy functioning. An alternative strategy, shown herein, is to boost the energy producing capacity of the demyelinated axon. Whilst previous studies have shown that axonal mitochondrial transport can be increased by targeting mitochondrial biogenesis, through PGC1α over expression, as a potential therapy for neurodegenerative disorders [50], this potential therapeutic strategy, has not been applied to demyelinating disorders. The inventors have shown that increased transport of mitochondria from the neuronal cell body to the axon makes ARMD more efficient and protects the acutely demyelinated axon. Given the suboptimal nature of the homeostatic ARMD, the strategy of increasing mitochondrial biogenesis and axonal transport is ideally suited for demyelinating disorders. Therefore provided herein is a mechanism that can be therapeutically targeted — within the necessary short time frame — for neuroprotection in demyelinating disorders.
The inventors undertook detailed analysis of mitochondria in DRG neuronal cell bodies from 18 progressive MS autopsy cases and 12 controls. Furthermore, they correlated mitochondrial changes within DRG neuronal cell bodies with mitochondrial changes within demyelinated axons, at the dorsal root entry zone, in spinal cord blocks. Complex IV deficiency and clonally expanded mtDNA deletions in DRG neurons, as observed in this study, were similar to those seen in cortical neurons and choroid plexus epithelial cells in MS, although the respiratory deficiency affected a greater proportion of neurons in the DRG [7, 9]. Factors other than the energy shortfall due to the time lag of ARMD and inflammation induced damage to mitochondria are present which are intrinsic to the neuron that contribute to the energy deficit of the demyelinated axon. MtDNA deletion in single cells is not a reflection of the accumulation of ongoing damage to mtDNA. Clonal expansion of mtDNA is an active phenomenon that amplifies a mtDNA deletion in a single cell, as evident in a number of neurodegenerative disorders, including MS [29]. In MS, mtDNA deletions appear to be induced by the inflammatory process. These mtDNA deletions then undergo amplification through clonal expansion in metabolically highly active cells such as neurons and choroid plexus epithelial cells [8]. Given the clonally expanded mtDNA deletions in DRG neurons, together with the significant positive correlation between the extent of complex IV deficiency in proprioceptive DRG neuronal cell bodies and axonal mitochondrial content, the inventors suggest that complex IV deficient neurons attempt to trigger ARMD even more vigorously than neurons with healthy mitochondria.
The failure to identify respiratory deficient neurons in the brain, spinal cord and DRG following a detailed examination in nine experimental disease models, and tissue from spinal cord hemi-section, highlights a major short fall of the existing disease models in recapitulating neuropathological findings of progressive MS. There are multiple potential reasons for the lack of respiratory deficient neurons in existing models. First, oxidative injury that is implicated in the induction of mtDNA deletions is limited in established disease models compared with MS [60]. Second, these experimental disease models predominantly adopt young animals, which may have better repair and mitochondrial quality control mechanisms. Third, the clinicopathological course of animal models is relatively short compared with the disease duration of progressive MS. Finally, both chronic and ongoing acute demyelination, as evident in slowly expanding MS lesions, are relatively sparse in existing disease models compared with progressive MS [19]. The complex IV knockout mice used in this study help to determine the consequences of mitochondrial respiratory chain deficiency for the demyelinated axons. The inventor’s data in COX10Adv mutants indicate that the stimulation of mitochondrial biogenesis and mitochondrial dynamics can partly overcome the detrimental consequences of the complex IV deficiency in acutely demyelinated axons. The protective effect of increasing mitochondrial biogenesis in complex IV deficient neurons is likely to reflect the fact that such mitochondria are deficient, but not completely devoid of metabolic activity. Therefore, despite their deficiency, they exert a net positive effect, and help boost the overall energy producing capacity of the axon. The inventors therefore suggest that enhancing ARMD is a therapeutically tractable approach, particularly when combined with approved therapy in MS as well as HIV neuropathy and diabetic neuropathy, where complex IV deficiency is an additional contributor to the axonal energy failure [6, 9, 14, 78].
In demyelinating disorders, axon degeneration is most prominent in areas with acute demyelination. In MS, neuropathological studies have shown that demyelination is ongoing throughout the clinical course of the disease. During the early stage of MS, there is an abundant formation of acutely demyelinating lesions [19]. In progressive MS, there is still ongoing demyelination, particularly at the edge of chronic active or slowly expanding lesions even at the end stages of MS. [19, 35] MRI imaging provides robust evidence of new lesions in early stage and slowly expanding lesions [1, 11, 19]. In terms of neuronal mitochondria, factors that amplify mitochondrial injury, such as oxidative stress and iron accumulation, likely require time to compromise the neurons [37]. The inventors consider that respiratory deficiency within neurons becomes more prominent with increasing disease duration in MS. Thus, the inventors consider their findings in both wild type mice and COX10Adv mutant mice show that the neuroprotective strategy discussed herein is applicable to the entire disease course of MS.
In summary, the inventors have determined that where mitochondria within neuronal cell bodies respond to the increased energy demands of demyelinated axons by moving to the axon (ARMD):
The neuroprotective strategy proposed by the inventors is to protect acutely demyelinated axons from damage. For example, in progressive MS rather than relapsing disease, wherein neuropathological studies and MRI measurements show that there is ongoing demyelination in progressive MS, particularly at the edges of chronic active lesions which are slowly expanding even with optimal disease modifying therapy and at the later stage of progressive MS (at autopsy), this strategy provides an advantageous treatment option which was not considered as demyelination was previously not considered not to correlate well with disability in progressive MS.
Cerebellar slices were prepared as previously described [4]. Briefly, wild type C57BL/6 and Shiverer mice pups were sacrificed at P10 and cerebellum was placed in ice-cold dissection medium. The sagittal slices were then sectioned into 300 µm thick slices and placed on a membrane insert. Picospritzer III (Parker, US) and a micromanipulator was used to inject mEOS2-Lentivirus (titre 7-8*109; aliquots stored at -80° C.) containing 0.025% of Fast-Green (FG, Sigma F7258, UK) in to the Purkinje cell body layer. To enhance activation of the CMV-promoter driven mEOS2 construct, 10 µM of Forskolin (Forskolin Coleus forskohlii, 344282 Sigma) was added to the slice culture medium the day after injection and removed 2 days later. To demyelinate cerebellar slices, the inventors used lysolecithin (L-α-Lysophosphatidylcholine; L4129 Sigma), which minimally impacts mitochondrial function [4]. 0.75 mg/ml Lysolecithin was added to the medium for 17 hours at DIV13. For the time course experiments of the ARMD, 0.5 mg/ml lysolecithin was added to the medium for 17 hours. The slices were then fixed and stained using immunofluorescence histochemistry at several timepoints after removal of lysolecithin to determine changes in axonal mitochondrial parameters and axonal bulbs. Only demyelinated axons that were not transected were chosen for axonal mitochondrial analysis.
Cloning and preparation of Lentivirus was performed as previously described [41]. Miro1 and PGC1α plasmids were sourced from Addgene (pRK5-Miro1, plasmid #47888; AAV-CMV-Flag-PGC1α-6His, plasmid #67637). Miro1 was inserted into a pDONR-P2A-mKate2 vector. The pDONR-P2A-mKate2 vector was used as a negative control and as an axonal marker in live imaging experiments. PGC1α was inserted into a pDONR-P2A-eGFP. The m1 m4-eGFP (kind gift from Alan Peterson and Anna Williams) was amplified using primers with attB sites and cloned into a pDONR vector. All plasmids were shuttled into a lentiviral backbone pLenti6-cppt-delta CMV-DEST-opre, as described previously11. The viral titers were as follows mEOS2 8.2*109 cfu/ml, Miro1 5*108 cfu/ml, PGC1α 1.4*108 cfu/ml, mKate2 2.25*109 cfu/ml, m1m4-eGFP 6.74*109 cfu/ml.
Live imaging of mitochondria in Purkinje cell axon was performed at DIV14, directly after removing the lysolecithin. Mitochondria in the most proximal 50 µm segment of the Purkinje cell axon were photoconverted using the 405 nm laser at 3% laser power for 20 seconds [34]. Immediately after photoconversion, the 85 µm long proximal axonal segment was imaged every minute for 20 minutes. An 8-12-micron stack was created from images every 0.5 micron in depth. Time lapse images were used to generate videos, exported from the Zeiss software, while all further analysis was done in Fiji [59]. Newly transported mitochondria, either appearing from the neuronal cell body to the most proximal 20 micron axonal segment or distal axonal mitochondria appearing in the 20 microns long axonal segment of the most distal photoconverted segment, were counted visually and confirmed using the kymograph. Green mitochondria represent newly transported mitochondria and red labelled mitochondria represent pre-existing mitochondria in the proximal axonal segment. For each mitochondrion appearing, the direction of movement was noted, as well as the area of the mitochondrion was measured manually, using the measure function in Fiji, when it first appeared in the axon.
Kymographs of the time lapse images were generated by using the ImageJ plugin KymographClear2.0 [40]. Mitochondrial speed of movement was determined by using the Kymotoolbox ImageJ plugin [80]. The mitochondria moving anterograde from the cell body to the axon were identified by the slope direction of tracks within the 20 micrometers of the kymograph and subsequently confirmed on the video. For retrograde moving mitochondria 20 micrometers of the most distal part was used.
The inventors used spectral confocal reflectance microscopy (SCoRe) to determine the myelination status of the axons [58]. Specificity of SCoRe, to differentiate demyelinated axons from myelinated axons, was confirmed by immunofluorescence staining for Myelin Basic Protein (MBP) and neurofilament and then overlapping it with SCoRe image.
The membrane inserts containing cerebellar slices were cut out and fixed in PFA before heat mediated antigen retrieval. After blocking with Normal goat serum (NGS, Vector S-1000, US), the free floating slices were incubated with three primary antibodies (Table 3), and then exposed to secondary antibodies, before mounting using Vectashield with DAPI (Vector H-1200, US) [52]. Confocal images of triple staining were acquired on a Zeiss LSM 710 inverted confocal microscope (Zeiss, Germany). To quantitate axonal mitochondria, images were processed in Adobe Photoshop CS6 (Adobe, US) and all non-axonal mitochondria (outside the NF+ structures) were removed. Images were then opened in Fiji and individual axons were cut out to analyse the axonal mitochondrial parameters using macros. The first macro split the images into the separate colour channels, the second macro measured the axonal area and the third macro measured the axonal mitochondrial number and area. For each slice, 40 axons were chosen and the mean axonal mitochondrial occupancy was calculated for each data point, which represents a slice from a different animal. For the analysis of axonal bulbs, images of NF labelling were acquired as mentioned above and the axonal bulbs per field of view in x63 images were counted. For each cerebellar slice 5 fields of view were randomly selected and the axonal bulb were counted and averaged for each datapoint.
Longitudinal cryosections, 15 micrometer thickness, of dorsal spinal cord were placed on glass slides and stored at -80° C. The triple immunofluorescent staining and confocal images were taken from wild type and mutant mice as well as human tissue and followed the same protocol as for the cerebellar slices.
For the analysis of axonal mitochondria, only the non-transected dorsal column axons were included. Acutely demyelinated experimental lesions were identified by DAPI staining and loss of MBP staining. Chronic MS lesions were identified by loss of MBP and serial sections were used for the mitochondrial analysis. Images were processed and analysed as described for cerebellar slices. For calculating mitochondrial complex IV deficiency in mouse spinal cord axons (wild type and mutant) and human dorsal column axons, the mitochondrial channels of complex II 70 kDa and COX-l were merged in Fiji. A macro was used to calculate the percentage of complex ll 70 KDa-positive regions that were co-labelled by COX-l for each axon. For each case, 40 axons were chosen and the mean axonal mitochondrial occupancy was calculated for each data point, which represents a different animal or human case. Axonal bulbs were quantitated as described for cerebellar slices.
For the analysis of axon number in dorsal columns of WT and COX10Adv mutant mice, frozen transverse sections of cervical spinal cord were fixed and stained, as described previously. The sections were then imaged on a Zeiss ApoTome.2 (Zeiss, Germany) with tile scan function and stitching to generate a single image file for the whole dorsal column. The total axon number per animal was determined using “analyse particle” function in FIJI. For the analysis of PGC1α-positive nuclei in DRG neurons, snap frozen spinal cord was cryosectioned longitudinally, fixed and stained for PGC1α, NF200 and peripherin. Images of the whole DRG were acquired and the percentage of PGC1α+ NF200+ cells was determined. For the analysis of mitochondrial respiratory chain subunits of the mitochondrial respiratory chain within human DRG neurons, the inventors triple stained using NF200, complex ll 70 kDa and a number of subunits. The percentage of DRG neurons that were deficient in mitochondrial respiratory chain subunits was determined in serial sections of human DRG.
Microfluidic chambers were fabricated in polydimethylsiloxane (PDMS) (Sylgard 184, Dow Corning, US) using standard soft lithography techniques, comprising of an array of microchannels between two culture chambers that are fluidically addressable via inlet/outlet wells, as previously described [36]. Prior to use, these devices were coated with 0.45 mg/ml Matrigel (Corning 356231, US) for 1 hour at RT and 30 mg/ml Poly-D-lysine (PDL, Sigma Aldrich P6407, UK) for 30 minutes at RT. To achieve fluidic isolation in a given chamber the inventors added at least 10µl more of the medium to the opposite chamber, which prevents diffusion from the treated to the untreated chamber, as previously shown [55, 56].
DRG neurons were rapidly extracted from P4-P8 old C57BL/6 mice pups, as previously described [64]. Differential adhesion was used to remove excess glial cells from the culture. After seeding the DRGs in seeding medium a concentration of 20 µM FUDR was added to the DRG neuronal cell body chamber and the axonal chamber to reduce growth of non-neuronal cells. A concentration gradient of 25 ng/ml NGF in the cell body chamber to 50 ng/ml NGF in axonal side was created to enhance axonal growth. The day after placing DRG neurons in the cell body chamber, the seeding medium was completely removed and replaced with maintenance medium. Until the 10 day after seeding, FUDR was added at a concentration of 10 µM to both sides of the chamber, while the NGF gradient was maintained for the same period. At 10 days after seeding Lentivirus expressing mKate2 was added to the cell body chamber at MOl 25 to label DRG neurons in the cell body chamber and their axons in the axonal chamber.
OPCs for myelinating cultures were obtained by dissection of Sprague Dawley rat cortices, as previously described [82]. Once cell count was done using a hemocytometer, M1-M4-eGFP lentivirus was added at MOl 40 to approximately 100,000 OPC. Oligodendrocyte precursor cells (OPCs) were seeded into the axonal chamber at 12 days following DRG seeding in the cell body chamber, in order to allow sufficient number of axons to have crossed into the cell body chamber [72]. Immediately following seeding of OPCs, the maintenance medium in both chambers was replaced with myelination medium [72]. Thereafter co-cultures were maintained for another 2 weeks, while renewing the myelination medium 2 times a week, to ensure adequate myelination prior to the visualization of myelinated axonal segments in live-imaging.
The inventors established that 0.005 mg/ml of lysolecithin for 2 hours was sufficient to demyelinate DRG-OPC co-cultures without damaging the DRG axons in unmyelinated cultures. Before adding lysolecithin to microfluidic chambers, the inventors used an Axio Observer Z1 inverted motorized microscope (Zeiss, Germany), for live imaging to identify the myelinated axonal segments (video 11, online resource). Images of the myelinated axonal segments were saved with x-y coordinates of the stage position. The effect of live imaging on the axons and myelin was determined by imaging microfluidic chamber containing both mKate2 expressing DRGs and eGFP-expressing OPC where imaged at 20x magnification (Plan-Apochromat 0.8 NA Ph 2 M27 objective, Zeiss, Germany) for 30 minutes before returning the microfluidic chambers to the incubator. Re-imaging 24 hours later showed that there was no significant effect of live imaging on axonal health.
The inventors then added lysolecithin for 2 hours before live imaging the previously imaged axonal segments again, using the x-y co-ordinate of the stage position. These live images of axons, pre and post lysolecithin, allowed the assessment of the demyelination of the axonal segments (based on M1-M4-eGFP fluorescence) as well as axonal damage following acute demyelination (based on appearance of mKate2 fluorescence). Axonal structure was categorized as intact, beaded or fragmented, both prior to and following exposure to lysolecithin. Intact axons showed continuous mKate2 fluorescence and beaded axons showed obvious irregularities in axon diameter without transection. Meanwhile, axons were classed as fragmented when the mKate2 fluorescence was disrupted and not continuous in at least one part of the axon. Nearly all myelinated axonal segments were intact prior to exposure to lysolecithin and only intact myelinated axons were considered for the assessment of axon damage following acute demyelination. Following exposure to lysolecithin, demyelination was confirmed based on disruption or loss of M1-M4-eGFP fluorescence. On average 12 myelinated axonal segments were included per microfluidic chamber. An average of data from 2-3 microfluidic chambers per batch of experiments were pooled to generate a single data point presented in
The inventors targeted anterograde movement of mitochondria in unmyelinated DRG neurons, by over expression Mitochondrial Rho GTPase1 (Miro1), using a lentivirus [22]. Furthermore, mitochondrial biogenesis in neurons was targeted by over expressing peroxisome proliferator-activated receptor gamma (PPAR-y) coactivator 1-alpha (PGC1α), using a lentivirus [25, 54]. The inventors then pharmacologically targeted mitochondrial biogenesis in neurons by using pioglitazone [44]. DRG were extracted as described previously and seeded on glass-bottomed 35 mm dish (µ-dish35mm, low Grid-500 ibiTreat, ibidi 80156, Germany). Lentivirus Miro1 at MOl 10 was added to the culture medium at seeding (3 weeks before live imaging) and Lentivirus PGC1α at MOl 10 was added at 2 and 4 days and 3 weeks before live imaging. Finally, 2 µM pioglitazone was added at 2, 4 and 6 days and 3 weeks before live imaging and renewed with each media change. The same manipulations were carried out in DRG neurons co-cultured with OPCs, which were added DIV12. Myelinated axonal segments were identified for confocal imaging using SCoRe, as previously described for cerebellar slices (
In order to avoid pioglitazone impacting oligodendrocyte lineage cells and myelinated axons, the drug was applied to the DRG neuronal cell body chamber at a concentration of 2 µM for 6 days prior to demyelination. Pioglitazone was renewed in the neuronal cell body chamber with each media change. Furthermore, PGC1α inhibitor [15 µM SR-18292 (SML2146, Sigma UK)] was added together with pioglitazone to neuronal cell body chamber [62]. Following 6 days of pioglitazone treatment of the neuronal cell bodies, with or without PGC1α inhibitor.
Following 6 days of pioglitazone treatment of the neuronal cell bodies the inventors added lysolecithin to the axonal chamber to demyelinate, as previously described.
Lentivirus Miro1 and Lentivirus PGC1α were applied to the neuronal cell body chamber at seeding and DIV16, respectively. At DIV26, lysolecithin was added to the myelinating chamber, as previously described. Axonal integrity of myelinated segments (before demyelination) and axonal damage following demyelination (of the same myelinated axonal segment) were quantified using live imaging, as previously described.
The cerebellar slices from wild type C57BL/6 mice pups (P10) were prepared as described and the slices were maintained on membrane inserts in culture for a week, before adding 40 µM pioglitazone (Sigma PHR1632, UK) to the culture medium. Two days following exposure to pioglitazone, culture medium was renewed and lysolecithin 0.5 mg/ml was added to the culture medium for 17 hours. Following the removal of lysolecithin, pioglitazone was replaced in the culture medium for 3 days until fixing and staining of the slices, as previously described. Triple immunofluorescent labelling and confocal microscopy were used to assess demyelination and axonal bulb formation as well as mitochondrial occupancy of non-transected and demyelinated axons, as previously described.
Live imaging of mitochondria located in the proximal segment of DRG axon, was performed with or without mitochondrial manipulations, as described above for cerebellar slices. Each data point on the graphs in
To assess the ARMD response, DRG neurons were seeded in microfluidic chambers and mEOS2 lentivirus was added at seeding. At DIV12, OPC were added to the axonal chamber to achieve myelination, as described previously. At DIV24, the chambers were imaged on a Leica SP8 microscope with temperature control at 37° C. and 5% CO2 flow with a 25x water immersion objective (Leica). Per chamber all mEOS2 positive mitochondria in axons within 2 fields of view in the axonal chamber and the adjacent microchannels were then converted using the 405 nm laser at 3% laserpower for 2 minutes. To assess ARMD chambers were demyelinated using 0.005 mg/ml lysolecithin for 2 hours. The chambers were then returned to the incubator overnight. The following day photoconverted regions were imaged to assess newly transported mitochondria (green) from the cell body chamber to the axonal chamber. SCoRe was used to determine the myelinated status of the axons. To analyse the amount of newly transported green mitochondria in the axonal chamber, 20 axons were randomly selected, cut out and saved as single axon images. Fiji was then used to calculate the proportion of green in red area. To calculate the axonal mitochondrial occupancy, the “analyse particles” function of Fiji was used to determine the mitochondrial area, which was then corrected for the length of the axonal segment. Each dot in
To determine the effect of Miro1, PGC1α and pioglitazone on lysosomal trafficking in DRG neurons, unmyelinated DRG neurons were seeded on glass-bottomed 35 mm dishes, as previously described. Miro1 was added at seeding, while PGC1α and pioglitazone were added to the DRG neurons at 10 days and 6 days before imaging, respectively. At DIV14 LysoTracker (LysoTracker Red DND-99, L7528 Invitrogen) was added to the culture medium at a concentration of 50 nM and incubated for 30 minutes at 37° C., before washing the LysoTracker off and adding live imaging solution to the DRG neurons. Live fluorescence imaging was performed as described for microfluidic chambers, using a 63x oil immersion objective (Plan-Apochromat 1.40 NA Oil DIC M27 objective, Zeiss, Germany). Videos and Kymographs were generated as described previously. The total number of lysosomes moving in both directions were counted on the kymograph and visually confirmed on the videos and the direction of movement for every single lysosome was noted. Each datapoint on
Sodium azide (Sigma S8032, UK) was used to inhibit complex IV in unmyelinated DRG neurons, cultured on glass bottom dishes, as described previously [39]. Firstly, a concentration gradient experiment was performed to determine the sublethal sodium azide (Sigma S8032, UK) dose for DRG neurons, which inhibits complex IV, by trypan blue exclusion test [67]. The highest dose, which did not impact cell viability and resulted in complex IV inhibition, was determined as 100 µM sodium azide for 17 hours, which was used for all the subsequent complex IV inhibition experiments. Complex IV histochemistry was performed as described below and images were obtained using bright field microscopy. The intensity of the complex IV reactive product was assessed using FIJI and densitometry to analyse complex IV activity at a single cell level.
For live imaging of mitochondrial dynamics in complex IV deficient DRG neurons, unmyelinated DRG neurons were cultured on glass bottom dishes, as described previously. Lentivirus mEOS2 was added at seeding and live imaging was performed at DIV21, as described previously. Kymograph were prepared and mitochondria were analysis as described previously for Purkinje cell axons in cerebellar slices.
DRG neuronal cells were cultured on V7 Seahorse 24-well cell culture microplates (Agilent Technologies), in maintenance medium in a 5% CO2 37° C. incubator. Sodium azide was present in media at either 0.1 or 1 mM for 17 hours before the Seahorse experiment, and the sodium azide was maintained in the media during the Seahorse run. Plates were incubated for 30 mins at 37° C. (without CO2), before entry into the Seahorse XFe24 Extracellular Flux Analyser (Agilent). Three measurements were taken basally, and three measurements taken after injection of each drug to either inhibit ATP-linked respiration, uncouple respiration or inhibit the respiratory chain. Mitochondrial respiration was calculated by subtracting the first OCR measurement following injection of antimycin/rotenone from the third basal OCR measurement. Normalisation of OCR to relative protein content was achieved following Sulforhodamine B (SRB) staining of all cell wells. Data for each treatment groups was averaged from between 4-5 replicate wells.
Frozen human autopsy tissue was obtained, including dorsal root ganglia and spinal cord blocks, from the rapid autopsy program at Cleveland Clinic, Ohio, USA and Netherland Brain Bank (Table 1). The frozen tissue blocks were stored at -80° C. until cryosectioning. The entire DRG were cryosectioned at 15 micrometers intervals. Cryosections were then subjected to COX/SDH histochemistry, COX/immunofluorescent labeling as well as laser micro dissection of single neurons, as described below.
Mitochondrial respiratory chain complex IV(COX)/complex ll (succinate dehydrogenase [SDH]) activity was assessed using the well-established sequential COX/SDH histochemistry, as previously described[9]. In five randomly chosen DRG cryosections, complex IV deficient neurons (stained blue) were calculated as a percentage of total neurons (sum of neurons stained either brown or blue) in both frozen human (Table 1) and frozen mouse tissue (Table 2 and COX10Adv mutant mice). For the detection of complex IV deficient cells with intact complex ll within the brain spinal cord of the animal models (Table 2), the inventors stained every 5th section of the entire brain and spinal cord and scanned the sections at x40 objective manually to look for cells stained blue (complex IV deficient with intact complex II).
To identify complex IV in proprioceptive and nociceptive DRG neurons, NF200 and peripherin were immunofluorescently labelled following completion of complex IV histochemistry step, as previously described [38]. Both brightfield and fluorescent images of five randomly chosen DRG cryosections were obtained using Zeiss ApoTome.2 microscope (Zeiss, Germany) and superimposed using ImageJ to identify complex IV activity within proprioceptive and nociceptive DRG neurons. Proprioceptive neurons were identified as NF200+peripherin-. To identify complex IV deficient CNS cells in animal models, independent of complex ll activity, the inventors performed sequential COX/immunofluorescent histochemistry and used antibodies against COX-l and complex ll 70 kDa (Table 3), as previously described [38]. To look for immunofluorescently labelled cells, the inventors stained every 5th section of the entire brain and spinal cord, except marmoset EAE, where tissue blocks were used, and manually scanned the sections at x40 objective.
Cryosections (15 µm thick) were mounted onto membrane slides (Leica) for laser micro dissection. Following COX/SDH histochemistry, single DRG neurons were micro dissected using a Leica laser micro dissection microscope (Leica LMD), as previously described[9]. Spinal cord grey matter regions from snap frozen tissue was micro dissected from animal models (Table 2), except in cuprizone model where approximately 250 × 250 µm2 region of cortex was included. DNA extraction was carried out using the QIAamp DNA Micro Kit (Qiagen).
Real-time PCR, as previously described [9], was used to analyse the level of mitochondrial DNA deletion in single DRG neurons in MS tissue. Known deletion-level standards, a blood-positive control and a blood-negative control, run in triplicate, were added to the assays. Long-range PCR, as previously described [9], was used to detect mtDNA deletions in human autopsy tissue and in snap frozen tissue from animal models.
One in every 5 serial sections of each DRG was processed using cresyl violet staining and the total number of DRG neurons with nuclei was counted per DRG section for each animal and human case. An average of 4-5 DRG per animal and human case was included in each data point shown in
To generate inducible knockout of complex IV subunit 10 (COX10) in DRG neurons, the inventors crossed COX10flox/flox mice with AdvillinCreERT2/+ mice to derive COX10flox/flox AdvillinCreERT2/+ mutant mice (COX10Adv mutants) [13, 48]. Wild type and COX10Adv mutant mice were maintained on C57Bl6 background. Mice were genotyped, as previously described [13, 48]. Tamoxifen was dissolved in sunflower oil/ at 20 mg/ml and gavaged at a dose of 60 ul/10 g body weight daily over 5 consecutive days. On an Applied Biosystems 7500 Fast Real Time PCR system in triplicates, qPCR was performed using 10 ng of genomic DNA in a 12.5-µl assay using PowerSYBR Green PCR Master Mix (Applied Biosystems). A 167-base-pair Cox10flox-specific fragment was obtained with primers 5′-CGGGGATCAATTCGAGCTCGCC-3′ and 5′-CACTGACGCAGCGCCAGCATCTT-3′. All animal experiments were performed in compliance with Animals (scientific procedures) Act 1986 and UK Home Office guidelines under the animal license (PPL 70/7872). Tissue from established animal models was obtained through collaborations as listed in Table 2.
Both wild type mice and COX10Adv mutant mice of C57Bl6 background, aged approximately 13 weeks, were anaesthetized using inhalation of 3-4% isoflurane/oxygen with supplementation of 0.05 ml of buprenorphine administered subcutaneously. Following exposure of spinal vertebrae at T12/T13, a dorsal laminectomy was performed to expose the dura and the central vein. Dura just lateral to the central vein was pierced using a sterile dental needle. The tip of a pulled glass capillary, attached to a Hamilton syringe, was introduced into the dorsal column through the pieced dura at an angle of 45 degree, approximately, and 0.05 µl of 1% lysolecithin was injected to cause focal demyelination of the dorsal column in mice. Wild type mice were euthanized at 3, 5, 7 and 9 days post lesioning for the time course experiments (
Both wild type mice and COX10Adv mutant mice of C57Bl6 background were subjected to no more than two behavioral tests, following a period of training. Animal in the survival experiment that reached a moderate severity as defined in the project license were culled using a Schedule 1 method.
Mice were euthanized using an overdose of pentobarbitone (200 mg/ml) and perfused intravascularly with 2.5% glutaraldehyde and 4% paraformaldehyde in 0.1 M sodium cacodylate buffer. Following post fixing of the spinal cord, tissue was prepared, embedded in Durcupan resin and stained, as previously described [63]. A JEOL JEM-1400 Plus transmission electron microscope was used with Gatan one view digital camera and Digital Micrograph 3 software at x5700 magnification to image dorsal column axons in cross section. To calculate the g ratio, the cross-sectional area of the axon, both including and excluding myelin ring, was determined using the freehand tool on ImageJ software, which enable the radius of the axon and radius of the axon plus myelin ring to be calculated to determine the g-ratio. At least 100 dorsal column axons in the gracile fasciculus in the thoracic spinal cord were included for each mouse.
To investigate whether COX10 deficiency or focal dorsal column demyelination impact on neurotransmission at the first central synapses of DRG neurons, synaptoneurosomes from dorsal column nuclei (DCN) [24, 73] were prepared. Protocols that optimise metabolic and ionic integrity in synaptoneurosomes have been recently developed so dynamic Ca2+ fluorescence responses to receptor stimuli can be measured [43, 68, 74]. The selective AMPA receptor agonist, R,S-AMPA (Abcam) with the selective inhibitor of AMPA receptor desensitization, cyclothiazide (Tocris) or the Ca2+ ionophore, ionomycin (Abeam), were added immediately before recording. Intracellular Ca2+ fluorescence was read at excitation 488 nm, emission 518 nm. Ionomycin (10 µM) and basal measurements were included in every plate to calibrate the dynamic range of the assay. Mean responses were calculated over the first 4 min following drug addition.
Axonal complex IV activity and complex IV subunit-I: COX histochemistry was combined with triple immunofluorescent histochemistry, using with antibodies against neurofilament, complex IV subunit-I and complex II 70 kDa. This staining was done to assess: 1) complex IV activity in single axons, and, 2) identify complex IV-deficient axonal mitochondria and, subsequently, assess the complex subunit status of mitochondria that lack complex IV activity. This sequential technique, which is performed in the same tissue section and has been described and validated in previous publications, is based on the observation that only the mitochondria lacking complex IV activity are immunofluorescently labeled following COX histochemistry, because the brown deposit of COX histochemical reaction in complex IV active mitochondria prevents the immunolabeling of the mitochondrial respiratory chain complex subunits. COX media consisted of 100 µM cytochrome c, 4 mM diaminobenzidine tetrahydrochloride and 20 µg/ml catalase in 0.1 M phosphate buffer pH7.0. Cryosections were incubated at 37° C. for 30 min and washed in PBS. Cryosections were then proceeded through the triple label immunofluorescent histochemistry steps, as stated above. Secondary antibodies were as follows: anti-mouse IgG2a 488, Life Technologies; anti-mouse IgG1 633, Life Technologies; anti-chicken 488 respectively). The sequentially stained sections were mounted in glycerol with Hoechst nuclear stain and stored at -20° C. until required for imaging by the Zeiss Imager Z1 Apotome 2 microscope.
Sequential COX histochemistry and immunofluorescent histochemistry: brightfield images of complex IV activity and immunofluorescent labeling of axons as well as mitochondria that lack complex IV activity, due to the blocking of immunolabeling by the deposits of complex IV histochemical reaction, were obtained using the Apotome microscope. SCoRE was used to ensure confirmation of myelinated and demyelinated axons in these sections.
In adjacent sections complex IV activity and immunofluorescent labeling of APP and synaptophysin were similarly captured. Images were taken using a x63 oil lens and brightfield and FITC, TRIC and Cy5 channels were imaged sequentially.
Brightfield microscopy: 1 in 5 serial cryosections of the entire brain and/or entire length of the spinal cord, stained for COX/SDH, were viewed on an Olympus BX51 microscope at x20 magnification to screen for respiratory-deficient cells with intact complex II activity (stained blue) by two investigators independently.
GraphPad Prism® software, version 6.0 (GraphPad Software Inc, US) was used for statistical analysis. For normally distributed data, a two-way student’s t-test was used to determine statistical significance, while One-way ANOVA was used for multiple column comparisons. For data that was not normally distributed the two-tailed ‘Mann-Whitney-U’ test was selected as a non-parametric test, while multiple column comparisons were done by using the Kruskal-Wallis test. Unless otherwise specified, data is represented as the average ± standard deviation (SD). A p-value < 0.05 was regarded as being significant and designated *-**** in the graphs.
The inventors considered that mitochondria within healthy neuronal cell bodies respond to demyelination by moving to the axon. Therefore, the inventors labelled mitochondria with a photoconvertible dye (mito-mEOS2) and performed live imaging over 20 minutes to visualise mitochondria that enter the myelinated and demyelinated axons from the cell body in cerebellar slices (
In order to study the effects of demyelination on mitochondria in DRG neuronal cell body versus axon, which projects to the central nervous system and peripheral nervous system, the inventors cultured myelinated DRG neurons in microfluidic chambers (
Because the increased transport of mitochondria from the neuronal cell body to the axon upon demyelination requires time to build up axon mitochondrial content in the demyelinated axon, the inventors quantitated changes in axonal mitochondrial content over time. ARMD peaked at 5 days post demyelination in cerebellar slices and at 7 days post demyelination of centrally protecting dorsal column axons of DRG neurons, in vivo. To examine the impact of ARMD on axonal health, the inventors compared the temporal changes of axonal degeneration, indicated by the formation of axonal bulbs [70], with that of axonal mitochondrial content (
Given that the movement of mitochondria from the neuronal cell body to increase the mitochondrial content of the acutely demyelinated axon is a relatively protracted process compared with the rapid degeneration of the axon, the inventors aimed to determine whether the influx of mitochondria from the cell body to the axon can be increased by over-expression of Mitochondrial Rho GTPase1 (Miro1), which is known to facilitate mitochondrial transport by tethering mitochondria to a motor/adaptor protein complex [22]. This was found to significantly increase the movement of mitochondria from the cell body to the axon in unmyelinated DRG neurons (
In order to assess whether enhancing the mobilisation of mitochondria from the neuronal cell body to the axon alone or in combination with increased biogenesis could protect the acutely demyelinated axons from degeneration, the inventors considered three experimental systems. First, they found that the over-expression of Miro1, PGC1α, or the application of pioglitazone specifically to the DRG neuronal cell bodies in microfluidic chambers, significantly decreased the fragmentation of acutely demyelinated axons and significantly increased the number of intact demyelinated axons (
As pioglitazone protection of acutely demyelinated axons could in principle be due to improved myelin debris clearance and peroxisomal function in neurons, impaired microglial activation or targeting of PGC1a in neurons, PGC1a and mitochondria were assessed within DRG neurons in wild type mice that received dietary pioglitazone.
In disease states, such as progressive MS, there is perturbation to the function of mitochondria in neurons, exemplified by complex IV deficiency, the terminal complex of the electron transport chain. Complex IV deficiency is known to impair anterograde mitochondrial transport in myelinated axons and deplete the mitochondrial content of myelinated axons [6, 9, 14, 32, 33, 53, 78]. This raises the question whether mitochondria in these complex IV deficient neurons in disease states can respond to demyelination. Therefore, the inventors considered the relevance of ARMD to demyelinating diseases with complex IV deficient neurons, by examining respiratory deficient DRG neurons in MS autopsy tissue and the mitochondrial parameters of their demyelinated axons at the dorsal root entry zone [6, 9, 14, 78].
The inventors studied DRG neuronal cell bodies and their demyelinated centrally projecting axons in the spinal cord dorsal columns in progressive MS, as this enabled the accurate identifications of mitochondria in cell bodies and associated demyelinated axons. The inventors found approximately one third of neuronal cell bodies in DRG of MS to be complex IV deficient (
To investigate ARMD in complex IV deficient neurons, the inventors studied 9 distinct experimental models of demyelination that are pertinent to MS and a model of traumatic axonal transection (Table 2). However, they did not find complex IV deficient neurons within the brain, spinal cord or DRG in any of these models (
Given that complex IV deficient neurons demonstrate ARMD, the inventors tested whether transport of mitochondria from complex IV deficient neuronal cell bodies to the axon can be enhanced by targeting mitochondrial over-expression of Miro1, PGC1α and pioglitazone treatment. The inventors inhibited complex IV and therefore mitochondrial respiration in mature DRG neurons, in vitro, by using sodium azide (SA), which resulted in a significantly decreased anterograde transport of mitochondria, as expected (
To determine whether the protection of acutely demyelinated axons in COX10Adv mutant mice affects functional connectivity, the inventors evaluated the excitability of the first central synapses of the dorsal column axons in the dorsal column nuclei (DCN). The inventors isolated functionally intact synapses from DCN, using synaptoneurosomal preparations, and exposed to AMPA receptor agonists to assess Ca2+ responses. AMPA-induced Ca2+ fluorescence responses of freshly prepared DCN synaptoneurosomes were significantly reduced in COX10Adv mutant mice compared to wild type controls and the deficit was exacerbated 3 days following dorsal column demyelination (
The inventors have shown demyelination creates a state of energy deficiency in the axon, through insufficient energy producing capacity, despite a homeostatic mechanism, termed ARMD, whereby mitochondria move from the cell body to the axon and gradually increase the mitochondrial content of the demyelinated axon. The protection of acutely demyelinated axons by enhancing ARMD further support the existence of an energy deficient state in acutely demyelinated axons. The inventors consider myelination during development and the resulting energy efficiency of nerve impulse conduction decreases the requirement for mitochondria in the axon (brake on) and demyelination undo the energy efficient state and increase the need for mitochondria in disease states (brake off), necessitating ARMD. During the timeframe until the homeostatic ARMD reaches its optimal level, the acutely demyelinated axon is particularly vulnerable to degeneration. A brake on mitochondria by myelin is elegantly illustrated by the healthy optic nerve, where mitochondria are sparsely distributed in the myelinated axonal segments compared with the abundance of mitochondria within the unmyelinated segments in laminar cribrosa. Furthermore, myelinated axons in wild type mice contain less mitochondria than those with mutation of myelin genes, where myelination is incomplete.
The inventors consider the neuroprotective strategies discussed herein can be utilised to preserve the acutely demyelinated axons, and then neuroregenerative therapies to remyelinate these axons can be provided. Remyelination addresses the long term saving of axons (chronically demyelinated) that have survived the acute myelin attack. The inventors strategy to enhance ARMD is about making more axons survive the attack on myelin, so that they can subsequently be remyelinated. For remyelination to save the acutely demyelinated axons it needs to occur rapidly, before the homeostatic ARMD is completed (within the first few days of demyelination). Even if extremely efficient remyelination is achieved such axons are likely to undergo repeated demyelination in the hostile microenvironment. Furthermore, remyelination is an imperfect regenerative process, in terms of axonal mitochondria. The inventors have found that the mitochondrial content of remyelinated axons remained elevated relative to myelinated axons. Nevertheless, remyelination therapy can be used to regulate the axonal mitochondrial content and avoid potential long-term adverse effects of increasing axonal mitochondrial content following enhanced ARMD.
In summary, the inventors have determined a compensatory role for mitochondria as part of the neuronal response to demyelination. Although the mobilisation of mitochondria from the neuronal cell body to the axon occurs spontaneously following the destruction of myelin, the resultant increase in the mitochondrial content of the demyelinated axon, which the inventors have termed homeostatic ARMD, is too protracted. Enhancing ARMD, by increasing the transport of mitochondria from the neuronal cell body to the axon as well as mitochondrial biogenesis in the neuron, protects the acutely demyelinated axon. This novel neuroprotective strategy is considered to be applicable to all demyelinating disorders, even when neurons are respiratory chain deficient. Hence, drugs that enhance ARMD are important to protect the vulnerable acutely demyelinated axons, so that regenerative strategies, like remyelination, can be effectively implemented in demyelinating CNS and PNS disorders.
Although the invention has been particularly shown and described with reference to particular examples, it will be understood by those skilled in the art that various changes in the form and details may be made therein without departing from the scope of the present invention.
The inventors assessed the mitochondrial content of demyelinated axons in nine different disease models at peak clinical disease or peak demyelination time point, when a clinical phenotype is not apparent (Table 4) This was then compared with myelinated axons in controls (Table 5). Mitochondria within demyelinated axons are evident in confocal images based on immunofluorescent labeling of porin, which is a voltage gated anion channel (VDAC) expressed in all mitochondria, neurofilament and myelin basic protein (MBP) (
Mitochondrial content (column two) is expressed as a percentage of axonal area occupied by porin labelled elements. Mitochondrial size (column three) and mitochondrial number (column four) are based on the area and number, respectively, of porin labelled elements within axons in confocal images. Shaded rows indicate mean values for myelinated axons from controls and unshaded rows mean indicate values for demyelinated axons. EAE: experimental autoimmune encephalomyelitis. LPC: lysolecithin. LPS: lipopolysaccharide. TCR tg: T-cell receptor transgenic. TMEV: Theiler’s murine encephalomyelitis virus. Values indicate mean ± standard deviation. *p<0.05, **p<0.01 and ***p<0.001.
To determine whether the increased mitochondrial content within demyelinated axons is reflected at the functional level, the inventors assessed complex IV activity of mitochondria at a single axon level using sequential COX histochemistry and immunofluorescent labelling of axons in snap frozen serial cryosections (
Mitochondrial respiratory chain complex IV active mitochondria in axons (column two) are assessed as a percentage of axonal area occupied by these complex IV active mitochondria. Complex IV subunit-l is assessed in all axonal mitochondria as the percentage area of the subunit present within the axons (column three) in triple labeled images. When axonal mitochondria that lack complex IV activity are detected (using complex II 70 kDa labeled elements within axons by the sequential COX histochemistry and triple labeling technique), the percentage area of complex IV subunit-I labeling in the mitochondria are not significantly different between myelinated axons in controls and demyelinated axons in all the disease models (last column). Shaded rows indicate values for myelinated axons and unshaded rows indicate values for demyelinated axons. EAE: experimental autoimmune encephalomyelitis. LPC: lysolecithin. LPS: lipopolysaccharide. TCR tg: T-cell receptor transgenic. TMEV: Theiler’s murine encephalomyelitis virus. Values indicate mean ± standard deviation. *p<0.01 and **p<0.001.
In axonal mitochondria that lack complex IV activity, the extent of complex IV subunit-I (COX-I) labelling was similar in demyelinated axons compared with myelinated axons, suggesting that that the lack of complex IV activity is not caused by the loss of complex IV subunit-I. To confirm that the complex IV subunit is intact in demyelinated axons, the inventors immunofluorescently co-labelled mitochondria and the subunit in serial sections and found a significant increase in complex IV subunit-I within demyelinated axons compared with myelinated axons (Table 6). The regions with inflammatory infiltrates in EAE showed a diffuse loss of complex IV activity and upregulation of iNOS. These findings suggest that complex IV activity is acutely inhibited and/or complex IV subunits are post-translationally modified by the inflammatory response in a proportion of axonal mitochondria that had responded to demyelination.
The inventors assessed the relationship between axonal mitochondrial parameters (content and complex IV activity) and axonal damage as indicated by the density of APP and synaptophysin positive elements (
In summary, the inventors have found:
| Number | Date | Country | Kind |
|---|---|---|---|
| 2009098.1 | Jun 2020 | GB | national |
| Filing Document | Filing Date | Country | Kind |
|---|---|---|---|
| PCT/GB2021/051478 | 6/14/2021 | WO |
